Conclusion: Fulvic acids can help treat HIV infection.
Title: Treatment of HIV infection with humic acid.
Type of Document: Patent
Takeaway: An extensive number of studies show that Humic extracts, specifically Fulvic acids, effectively and safely kill the HIV/Aids virus. One pharmaceutical company has patented a humic based drug that purifies blood for transfusions, killing the HIV virus without damaging blood cells.
Link: https://patents.google.com/patent/US20040137085A1/en
____________________________________________________________
Conclusion: Humic substances show antiviral properties against HIV-1.
Title: Antiviral activity of natural humic substances and shilajit materials against HIV-1: Relation to structure
Type of Document: Peer-reviewed journal article
Takeaway: The conclusion was made that the typical humic materials and Shilajit differ greatly in molecular composition, and the humic materials have substantial preferences as a natural source of antiviral agents as compared to shilajit.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554000/
____________________________________________________________
Conclusion: Shilajit reduces the resistance of HIV against antiretroviral therapy.
Title: Clinical Evaluation of Shilajatu Rasayana in patients with HIV Infection
Type of Document: Peer-reviewed journal article
Takeaway: The results show that Shilajatu (mineral pitch or Shilajit) decreases the recurrent resistance of HIV virus to ART and improves the outcome of the therapy.
Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215318/
__________________________________________________________
Conclusion: Humic acid interferes with the multiplication of HIV.
Title: Natural humic substances interfere with multiple stages of the replication cycle of human immunodeficiency virus
Type of Document: Conference abstract
Takeaway: The results showed that the humic acid (HA) and hymatomelanic acid (HMA) fractions exhibited a distinct antiviral activity within the concentration range from 0.78 ug/mL to 100 ug/mL with respect to HIV 1, while fulvic acids showed much less activity. Time of addition assay show that humic substances (HS) have antiviral activity at the stage of HIV fusion, and at the stage of reverse transcription of DNA to RNA, and at the stage of integration of viral DNA into the genome of the host cell. The results of HIV 1 cell attachment assay show that all HS blocked cellular HIV 1 attachment reducing an amount of the GFP-spots per cell.
Link: https://sci-hub.hkvisa.net/10.1016/j.jaci.2017.12.737
____________________________________________________________
Conclusion: Oxihumate may prevent HIV infection.
Title: Investigation of the anti-HIV properties of oxihumate
Type of Document: Peer-reviewed journal article
Takeaway: Oxihumate inhibited HIV-1 infection of MT-2 cells with an IC(50) of 12.5 microg/ml. Treatment of free and cell-attached HIV with oxihumate irreversibly reduced infectivity, while the susceptibility of target cells to the virus was not impaired by treatment prior to infection. The infectivity of the HIV particles was inhibited by interference with CD4 binding and the V3 loop-mediated step of virus entry. No viral resistance to oxihumate developed over a 12-week period in vitro.
____________________________________________________________
Conclusion: Oxihumate may stimulate the immune system in immunocompromised individuals.
Title: Investigation of the immunostimulatory properties of oxihumate.
Type of Document: Peer-reviewed journal article
Takeaway: Oxihumate increased the proliferative response of phytohaemagglutinin-stimulated human lymphocytes, from a concentration of 20μg/ml and upwards. This response was even more striking in the case of lymphocytes from HIV-infected patients and was not limited to the in vitro setting since similar effects were observed ex vivo following administration of a non-toxic dosage of 4 g oxihumate per day to HIV-positive individuals for two weeks. Oxihumate therefore holds promise for the treatment of immunocompromised patients.